Existing drugs for neurological and psychiatric disease are mostly symptomatic therapies rather than disease modifying. The challenge of the next generation of drug discovery in neuropsychiatric disease is therefore, (a) the development of analytical methods that can reliably identify cell-type specific disease-modifying drug targets and, (b) the challenge of training clinician scientists that span the drug development pipeline from novel target discovery to translational experimental medicine. In this project I will employ Mendelian Randomisation (MR) on a unique single-cell gene expression dataset measured in hundreds of thousands of cells from 63 neurologically normal fresh-frozen post-mortem human hippocampus and prefrontal cortex (BA46) samples. The dataset was established to investigate causal mechanisms and drug targets for epilepsy but is equally applicable to the investigation of human brain disease broadly. Here I propose to extend the current ongoing analyses in epilepsy to more diverse neurological and psychiatric diseases including behavioural traits such as memory and intelligence.